PTH and osteoporosis: Osteoporosis, the most prevalent skeletal remodeling disorder, is primarily treated by antiresorptive drugs inhibiting the differentiation and/or activity of osteoclasts.1 Although osteoanabolic treatment options, stimulating osteoblast-mediated bone formation, are available, they are not commonly used to treat osteoporotic patients.2 In the case of teriparatide, a fragment of parathyroid hormone (PTH), this is mostly explained by the relatively high costs and the mode of application (daily injection).